

# ForPatients

by Roche

Hemophilia A Severe Hemophilia A

## A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
14 Countries

**Trial Identifier**  
NCT04431726  
2020-001733-12,2023-505964-13-00  
MO41787

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to #12 months of age with severe hemophilia A (intrinsic factor VIII [FVIII] level <1%) without FVIII inhibitors. The study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 milligrams per kilogram of body weight (mg/kg) once every 2 weeks (Q2W) for 52 weeks. After 1 year of treatment, participants will continue to receive emicizumab (1.5 mg/kg once every week [QW], 3 mg/kg Q2W or 6 mg/kg once every 4 weeks [Q4W]) over a 7-year long-term follow-up period under this study frame.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

**NCT04431726 2020-001733-12,2023-505964-13-00 MO41787**  
Trial Identifiers

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=0 Months & <= 12 Months

**Healthy Volunteers**  
No